Characterization of presystemic elimination of trichloroethylene and its nonlinear kinetics in rats

Toxicology and Applied Pharmacology

Volumn 139, Issue 2, 1996, Pages 262-271

  Lee, K M ^a,c   Bruckner, J V ^a   Muralidhara, S ^a   Gallo, J M ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRICHLOROETHYLENE;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; GAS CHROMATOGRAPHY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALIA;

EID: 0030220584     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0165     Document Type: Article

References (46)

1. Andersen, M. E. (1981). A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state. Toxicol. Appl. Pharmacol. 60, 509-526.
2. Andersen, M. E., Gargas, M. L., Jones, R. A., and Jenkins, L. J. (1980). Determination of the kinetics constants for metabolism of inhaled toxicant in vivo using gas uptake measurements. Toxicol. Appl. Pharmacol. 54, 100-116.
3. Angelo, M. J., Pritchard, A. B., Hawkins, D. R., Waller, A. K., and Roberts, A. (1986). The pharmacokinetics of dichloromethane. I. Disposition in B6C3F1 mice following intravenous and oral administration. Food Chem. Toxicol. 24, 965-974.
4. ATSDR (Agency for Toxic Substances and Disease Registry) (1995). Toxicological Profile for Trichloroethylene. U.S. Public Health Service, Atlanta, GA.
5. Bruckner, J. V., Davis, B. D., and Blancato, J. N. (1989). Metabolism and carcinogenicity of trichloroethylene. Crit. Rev. Toxicol. 20, 31-50.
6. Bull, R. J., Templin, M., Larson, J. L., and Stevens, D. K. (1993). The role of dichloroacetate in the hepatocarcinogenicity of trichloroethylene. Toxicol. Lett. 68, 203-211.
7. Collins, J. M., and Dedrick, R. L. (1982). Contribution of lungs to total body clearance: Linear and nonlinear effects. J. Pharm. Sci. 71, 66-70.
8. Dallas, C. E., Gallo, J. M., Ramanathan, R., Muralidhara, S., and Bruckner, J. V. (1991). Physiological pharmacokinetic modeling of inhaled trichloroethylene in rats. Toxicol. Appl. Pharmacol. 110, 303-314.
9. Daniel, F. B., DeAngelo, A. B., Stober, J. A., Olson, G. R., and Page, N. P. (1992). Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male BC3F1 mouse. Fund. Appl. Toxicol. 19, 159-168.
10. Davidson, I. W. F., and Beliles, R. P. (1991). Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics. Drug Metab. Rev. 23, 493-599.
11. Dekant, W. (1993). Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation. Toxicol. Lett. 67, 151-160.
12. Dekant, W., Schulz, A., Metzler, M., and Henschler, D. (1986). Absorption, elimination and metabolism of trichloroethylene: A quantitative comparison between rats and mice. Xenobiotica 16, 143-152.
13. D'Souza, R. W., Bruckner, J. V., and Feldman, S. F. (1985). Oral and intravenous trichloroethylene pharmacokinetics in the rat. J. Toxicol. Environ. Health 15, 587-601.
14. Gargas, M. L., Burgess, R. J., Voisard, D. E., Cason, G. H., and Andersen, M. E. (1989). Partition coefficient of low molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98, 87-99.
15. George, C. F. (1982). Methods for distinguishing between the various sites of first-pass metabolism in man. In Clinical Pharmacology and Therapeutic 1. (C. F. George and D. G. Shand, Eds.), pp. 189-205. Butterworth Scientific, Boston.
16. Gibaldi, M., and Perrier, D. (1982). Absorption kinetics and bioavailability. In Pharmacokinetics. pp. 169-180. Dekker, New York and Basel.
17. Green, T., and Prout, M. S. (1985). Species differences in response to trichloroethylene. II. Biotransformation in rats and mice. Toxicol. Appl. Pharmacol. 79, 401-411.
18. Hall, S. D., McAllister, C. B., and Wilkinson, G. R. (1988). The assessment of bioavailability in the presence of nonlinear elimination. J. Pharmacokinet. Biopharm. 16, 263-278.
19. HAZDAT (1995). Agency for Toxic Substances and Disease Registry. Atlanta, GA.
20. Henschler, D. (1977). Metabolism and mutagenicity of halogenated olefins-A comparison of structure and activity. Environ. Health Perspect. 21, 61-64.
21. Huff, J. E. (1971). New evidence on the old problems of trichloroethylene. Ind. Med. 40, 25-33.
22. Ikeda, M. (1977). Metabolism of trichloroethylene and perchloroethylene in human subjects. Environ. Health Perspec. 21, 239-245.
23. Ikeda, M., Miyaka, Y., Ogata, M., and Ohmori, S. (1980). Metabolism of trichloroethylene. Biochem. Pharmacol. 29, 2983-2992.
24. Iwamoto, K., and Klaassen, C. D. (1977). First-pass effect of morphine in rats. J. Pharmacol. Exp. Ther. 200, 236-244.
25. Jochemsen, R., Hogendoorn, J. J. H., Dingemanse, J., Hermans, J., Boeijinga, J. K., and Breimer, D. D. (1982). Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans. J. Pharmacokinet. Biopharm. 10, 231-245.
26. Jusko, W. J., Koup, J. R., and Alvan, G. (1976). Nonlinear assessment of phenytoin bioavailability. J. Pharmacokinet. Biopharm. 4, 327-336.
27. Landrigan, P. J., Stein, G. F., Kaminsky, J. R., Ruhe, R. L., and Watanabe, A. S. (1987). Common-source community and industrial exposure to trichloroethylene. Arch. Environ. Health 42, 327-331.
28. Larson, J. L., and Bull, R. J. (1992). Species differences in the metabolism of trichloroethylene to the carcinogenic metabolites trichloroacetate and dichloroacetate. Toxicol. Appl. Pharmacol. 115, 278-285.
29. Lee, K. M., Muralidhara, S., Schnellmann, R., and Bruckner, J. V. (1995). Characterization of nonlinear kinetics of trichloroethylene in rats: Solvent-induced cytotoxicity following hepatic portal venous administration. Toxicologist 15.
30. Leibman, K. C., and Ortiz, E. (1977). Metabolism of halogenated ethylenes. Environ. Health Perspect. 21, 91-97.
31. Lesko, L. J. (1984). Nonlinear kinetics and theophylline elimination. In Pharmacokinetic Basis for Drug Treatment. (L. Z. Benet, N. Massoud, and J. G. Gambertoglio, Eds.), pp. 321-332. Raven Press, New York.
32. Miller, R. E., and Guengerich, F. P. (1982). Oxidation of trichloroethylene by microsomal cytochrome P450. Evidence for chloride migration in a transition state not involving trichloroethylene oxide. Biochemistry 21, 1090-1097.
33. Nakajima, T., Wang, R. S., Murayama, N., and Sato, A. (1990). Three forms of trichloroethylene-metabolizing enzymes in rat liver induced by ethanol, phenobarbital and 3-methylcholanthrene. Toxicol. Appl. Pharmacol. 102, 546-552.
34. Nomiyama, K., and Nomiyama, H. (1977). Dose-response relationship for trichloroethylene in man. Int. Arch. Occup. Environ. Health 39, 237-248.
35. NRC (National Research Council) (1986). Dose-route extrapolation: Using inhalation toxicity data to set drinking water limits. In Drinking Water and Health, Vol. 6, Chap. 6. National Academy Press, Washington, DC.
36. NTP (National Toxicology Program) (1990). Toxicology and Carcinogenesis Studies of Trichloroethylene in Fischer-344/N Rats andB6C3F1 Mice. NIH Publ. 90-1799. Dept. of Health and Human Services, Research Triangle Park, NC.
37. Prout, M. S., Provan, W. M., and Green, T. (1985). Species differences in responses to trichloroethylene. I. Pharmacokinetics in rats and mice. Toxicol. Appl. Pharmacol. 79, 389-400.
38. Richens, A. (1979). Clinical pharmacokinetics of phenytoin. Clin. Pharmacokinet. 4, 153-169.
39. Rocci, M. L., and Jusko, W. J. (1983). LAGRAN program for area moments in pharmacokinetic analysis. Comput. Prog. Biomed. 16, 203-216.
40. Routledge, P. A., and Shand, D. G. (1979). Presystemic drug elimination. Annu. Rev. Pharmacol. Toxicol. 19, 447-468.
41. Rubin, G. M., and Tozer, T. N. (1984). Theoretical considerations in the calculations of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics. J. Pharmacokinet. Biopharm. 12, 437-450.
42. Sanzgiri, U. Y., Kim, H. J., Muralidhara, S., Dallas, C. E., and Bruckner, J. V. (1995). Effect of route and pattern of exposure on the pharmacokinetics and acute hepatotoxicity of carbon tetrachloride. Toxicol. Appl. Pharmacol. 134, 148-154.
43. Staples, C. A., Werner, A. F., and Hoogheem, T. J. (1985). Assessment of priority pollutant concentrations in the United States using the STORET database. Environ. Toxicol. Chem. 4, 131-142.
44. Wagner, J. G. (1967). Method of estimating relative absorption of a drug in a series of clinical studies on which blood levels are measured after single and/or multiple doses. J. Pharm. Sci. 56, 652-653.
45. Watanabe, P. G., Young, J. D., and Gehring, P. J. (1977). The importance of nonlinear (dose-dependent) pharmacokinetics in hazard assessment. J. Environ. Pathol. Toxicol. 1, 147-159.
46. Westrick, J. J., Mello, J. W., and Thomas, R. F. (1984). The groundwater supply survey. J. Am. Water Works Assoc. 16, 52-59.